Xinh Tran, MD
Neurology · Houston, TXNPI 1871027292
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 24.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $229 and has fallen 91.5% since, to $19 in 2025. That places this record below the midpoint for neurology clinicians in TX, where the typical reported total is $2,170.
Across 29 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$154
- Teva Pharmaceuticals USA, Inc.$91
- Pfizer$75
- SK Life Science, Inc.$52
- Biogen$51
- Amgen$43
- plus $177 from 7 others
What the payments were for
- Food & beverage$644100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 6 | $154 |
| Teva Pharmaceuticals USA, Inc. | 3 | $91 |
| Pfizer | 4 | $75 |
| SK Life Science, Inc. | 2 | $52 |
| Biogen | 3 | $51 |
| Amgen | 2 | $43 |
| Biohaven Pharmaceuticals, Inc. | 2 | $42 |
| Argenx US, Inc. | 1 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| AstraZeneca | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Johnson & Johnson | 1 | $14 |
How this compares
$644 in reported general payments places this provider in the 35th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 19 | $13,794 |
| Memantine Hcl | 86 | $3,364 |
| Levetiracetam | 63 | $2,455 |
| Lacosamide | 15 | $2,269 |
| Donepezil Hcl | 154 | $1,459 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 23 | $654 |
| Quetiapine Fumarate | 22 | $578 |
| Memantine Hcl ErMemantine Hcl | 12 | $470 |
| Duloxetine Hcl | 14 | $459 |
| Pregabalin | 12 | $455 |
| Primidone | 12 | $433 |
| Gabapentin | 24 | $401 |
| Propranolol Hcl | 16 | $376 |
| Topiramate | 26 | $351 |
| ClopidogrelClopidogrel Bisulfate | 29 | $197 |
Paid to pharmacies, not to this prescriber.
Other neurology in Houston
- William OndoHouston$1.4M
- Pankaj SatijaHouston$1.1M
- Annette HowardHouston$826K
- Randolph EvansHouston$493K
- Leorah FreemanHouston$401K
- Mazen DimachkieHouston$388K
- Zsila SadighiHouston$361K
- Joseph JankovicHouston$323K
- Raja MehannaHouston$300K
- Eddie PattonHouston$299K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.